EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer

Alberto F Sobrero; Joan Maurel; Louis Fehrenbacher; Werner Scheithauer; Yousif A Abubakr; Manfred P Lutz; M Eugenia Vega-Villegas; Cathy Eng; Ernst U Steinhauer; Jana Prausova; Heinz-Josef Lenz; Christophe Borg; Gary Middleton; Hendrik Kröning; Gabriele Luppi; Oliver Kisker; Angela Zubel; Christiane Langer; Justin Kopit; Howard A Burris

doi:10.1200/JCO.2007.13.1193

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer

Alberto F Sobrero, Joan Maurel, Louis Fehrenbacher, Werner Scheithauer, Yousif A Abubakr, Manfred P Lutz, M Eugenia Vega-Villegas, Cathy Eng, Ernst U Steinhauer, Jana Prausova, Heinz-Josef Lenz, Christophe Borg, Gary Middleton, Hendrik Kröning, Gabriele Luppi, Oliver Kisker, Angela Zubel, Christiane Langer, Justin Kopit, Howard A Burris

Cancer and Genomic Sciences

Research output: Contribution to journal › Article › peer-review

769 Citations (Scopus)

Abstract

To determine whether adding cetuximab to irinotecan prolongs survival in patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine and oxaliplatin.

Original language	English
Pages (from-to)	2311-9
Number of pages	9
Journal	Journal of Clinical Oncology
Volume	26
Issue number	14
DOIs	https://doi.org/10.1200/JCO.2007.13.1193
Publication status	Published - 2008

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1200/JCO.2007.13.1193

Cite this

Sobrero, A. F., Maurel, J., Fehrenbacher, L., Scheithauer, W., Abubakr, Y. A., Lutz, M. P., Vega-Villegas, M. E., Eng, C., Steinhauer, E. U., Prausova, J., Lenz, H.-J., Borg, C., Middleton, G., Kröning, H., Luppi, G., Kisker, O., Zubel, A., Langer, C., Kopit, J., & Burris, H. A. (2008). EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. Journal of Clinical Oncology , 26(14), 2311-9. https://doi.org/10.1200/JCO.2007.13.1193

@article{b27be7cb1d7841c2ad5e77d703aff26d,

title = "EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer",

abstract = "To determine whether adding cetuximab to irinotecan prolongs survival in patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine and oxaliplatin.",

author = "Sobrero, {Alberto F} and Joan Maurel and Louis Fehrenbacher and Werner Scheithauer and Abubakr, {Yousif A} and Lutz, {Manfred P} and Vega-Villegas, {M Eugenia} and Cathy Eng and Steinhauer, {Ernst U} and Jana Prausova and Heinz-Josef Lenz and Christophe Borg and Gary Middleton and Hendrik Kr{\"o}ning and Gabriele Luppi and Oliver Kisker and Angela Zubel and Christiane Langer and Justin Kopit and Burris, {Howard A}",

year = "2008",

doi = "10.1200/JCO.2007.13.1193",

language = "English",

volume = "26",

pages = "2311--9",

journal = "Journal of Clinical Oncology ",

issn = "1527-7755",

publisher = "American Society of Clinical Oncology",

number = "14",

}

Sobrero, AF, Maurel, J, Fehrenbacher, L, Scheithauer, W, Abubakr, YA, Lutz, MP, Vega-Villegas, ME, Eng, C, Steinhauer, EU, Prausova, J, Lenz, H-J, Borg, C, Middleton, G, Kröning, H, Luppi, G, Kisker, O, Zubel, A, Langer, C, Kopit, J & Burris, HA 2008, 'EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer', Journal of Clinical Oncology , vol. 26, no. 14, pp. 2311-9. https://doi.org/10.1200/JCO.2007.13.1193

TY - JOUR

T1 - EPIC

T2 - phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer

AU - Sobrero, Alberto F

AU - Maurel, Joan

AU - Fehrenbacher, Louis

AU - Scheithauer, Werner

AU - Abubakr, Yousif A

AU - Lutz, Manfred P

AU - Vega-Villegas, M Eugenia

AU - Eng, Cathy

AU - Steinhauer, Ernst U

AU - Prausova, Jana

AU - Lenz, Heinz-Josef

AU - Borg, Christophe

AU - Middleton, Gary

AU - Kröning, Hendrik

AU - Luppi, Gabriele

AU - Kisker, Oliver

AU - Zubel, Angela

AU - Langer, Christiane

AU - Kopit, Justin

AU - Burris, Howard A

PY - 2008

Y1 - 2008

N2 - To determine whether adding cetuximab to irinotecan prolongs survival in patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine and oxaliplatin.

AB - To determine whether adding cetuximab to irinotecan prolongs survival in patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine and oxaliplatin.

U2 - 10.1200/JCO.2007.13.1193

DO - 10.1200/JCO.2007.13.1193

M3 - Article

C2 - 18390971

SN - 1527-7755

VL - 26

SP - 2311

EP - 2319

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 14

ER -

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this